Literature DB >> 10713797

A European perspective on social anxiety disorder.

Y Lecrubier1, H U Wittchen, C Faravelli, J Bobes, A Patel, M Knapp.   

Abstract

Epidemiologic surveys conducted across Europe indicate that the lifetime prevalence of social anxiety disorder in the general population is close to 7%. The disorder in adulthood rarely presents in its 'pure' form and 70-80% of patients have at least one other psychiatric disorder, most commonly depression. Social anxiety disorder is a risk factor for the development of depression and alcohol/substance use or dependence, especially in cases with an early onset (< 15 years). Individuals with social anxiety disorder have significant functional impairment, notably in the areas of initiation and maintenance of social/romantic relationships and educational and work achievement. The economic consequences of social anxiety disorder are considerable, with a high level of diminished work productivity, unemployment and an increased utilisation of medical services amongst sufferers. Effective treatment of social anxiety disorder would improve its course and its health and economic consequences.

Entities:  

Mesh:

Year:  2000        PMID: 10713797     DOI: 10.1016/s0924-9338(00)00216-9

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  16 in total

1.  Prospective associations between the cortisol awakening response and first onsets of anxiety disorders over a six-year follow-up--2013 Curt Richter Award Winner.

Authors:  Emma K Adam; Suzanne Vrshek-Schallhorn; Ashley D Kendall; Susan Mineka; Richard E Zinbarg; Michelle G Craske
Journal:  Psychoneuroendocrinology       Date:  2014-03-12       Impact factor: 4.905

2.  Resting regional brain metabolism in social anxiety disorder and the effect of moclobemide therapy.

Authors:  Alex Doruyter; Patrick Dupont; Lian Taljaard; Dan J Stein; Christine Lochner; James M Warwick
Journal:  Metab Brain Dis       Date:  2017-11-03       Impact factor: 3.584

3.  Explaining the association between anxiety disorders and alcohol use disorder: A twin study.

Authors:  Fartein Ask Torvik; Tom Henrik Rosenström; Kristin Gustavson; Eivind Ystrom; Kenneth S Kendler; Jørgen G Bramness; Nikolai Czajkowski; Ted Reichborn-Kjennerud
Journal:  Depress Anxiety       Date:  2019-03-05       Impact factor: 6.505

Review 4.  Social anxiety disorder in childhood and adolescence: current status and future directions.

Authors:  T B Kashdan; J D Herbert
Journal:  Clin Child Fam Psychol Rev       Date:  2001-03

5.  Social anxiety disorder in 11-12-year-old children: The efficacy of screening and issues in parent-child agreement.

Authors:  Hanne Kristensen; Svenn Torgersen
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-01-30       Impact factor: 4.785

6.  Social interaction anxiety and depression symptoms are differentially related in men and women.

Authors:  Hanjoo Kim; Elizabeth R Duval
Journal:  Curr Psychol       Date:  2022-06-27

7.  Mental disorders in primary care.

Authors:  Hans-Ulrich Wittchen; Stephan Mühlig; Katja Beesdo
Journal:  Dialogues Clin Neurosci       Date:  2003-06       Impact factor: 5.986

8.  The epidemiology of anxiety disorders: a review.

Authors:  Patrick Martin
Journal:  Dialogues Clin Neurosci       Date:  2003-09       Impact factor: 5.986

9.  Transcriptome and chromatin alterations in social fear indicate association of MEG3 with successful extinction of fear.

Authors:  Melanie Royer; Balagopal Pai; Rohit Menon; Anna Bludau; Katharina Gryksa; Rotem Ben-Tov Perry; Igor Ulitsky; Gunter Meister; Inga D Neumann
Journal:  Mol Psychiatry       Date:  2022-03-25       Impact factor: 13.437

10.  Social Phobia in an Italian region: do Italian studies show lower frequencies than community surveys conducted in other European countries?

Authors:  Mauro Giovanni Carta; Maria Carolina Hardoy; Mariangela Cadeddu; Bernardo Carpiniello; Liliana Dell'Osso; Mario Antonio Reda; Hans-Ulrich Wittchen
Journal:  BMC Psychiatry       Date:  2004-10-15       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.